tbuckley/cabot-search huggingface dataset:
Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer
Authors: Ka-wing Fong, Jonathan C. Zhao, Jung Kim, Shangze Li, Yeqing A. Yang, Bing Song, Laure Rittie, Ming Hu, Ximing Yang, Bernard Perbal, Jindan Yu
Journal: Cancer Research (2016)

The lethal phenotype of castration-resistant prostate cancer (CRPC) is generally caused by augmented signaling from the androgen receptor (AR). Here, we report that the AR-repressed gene CCN3/NOV inhibits AR signaling and acts in a negative feedback loop to block AR function. Mechanistically, a cytoplasmic form of CCN3 interacted with the AR N-terminal domain to sequester AR in the cytoplasm of prostate cancer cells, thereby reducing AR transcriptional activity and inhibiting cell growth. However, constitutive repression of CCN3 by the Polycomb group protein EZH2 disrupted this negative feedback loop in both CRPC and enzalutamide-resistant prostate cancer cells. Notably, restoring CCN3 was sufficient to effectively reduce CPRC cell proliferation in vitro and to abolish xenograft tumor growth in vivo Taken together, our findings establish CCN3 as a pivotal regulator of AR signaling and prostate cancer progression and suggest a functional intersection between Polycomb and AR signaling in CRPC. Cancer Res; 77(2); 412-22. ©2016 AACR.
Investigation of the First Seven Reported Cases of<i>Candida auris,</i>a Globally Emerging Invasive, Multidrug-Resistant Fungus — United States, May 2013–August 2016
Authors: Snigdha Vallabhaneni, Alex Kallen, Sharon Tsay, Nancy Chow, Rory Welsh, Janna Kerins, Sarah K. Kemble, Massimo Pacilli, Stephanie R. Black, Emily Landon, Jessica Ridgway, Tara N. Palmore, Adrian Zelzany, Eleanor H. Adams, Monica Quinn, Sudha Chaturvedi, Jane Greenko, Rafael Fernandez, Karen Southwick, E. Yoko Furuya, David P. Calfee, Camille Hamula, Gopi Patel, Patricia Barrett, Patricia Lafaro, Elizabeth L. Berkow, Heather Moulton-Meissner, Judith Noble-Wang, Ryan P. Fagan, Brendan R. Jackson, Shawn R. Lockhart, Anastasia P. Litvintseva, Tom M. Chiller
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Candida auris, an emerging fungus that can cause invasive infections, is associated with high mortality and is often resistant to multiple antifungal drugs. C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan (1). Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom (2-7). To determine whether C. auris is present in the United States and to prepare for the possibility of transmission, CDC issued a clinical alert in June 2016 informing clinicians, laboratorians, infection control practitioners, and public health authorities about C. auris and requesting that C. auris cases be reported to state and local health departments and CDC (8). This report describes the first seven U.S. cases of C. auris infection reported to CDC as of August 31, 2016. Data from these cases suggest that transmission of C. auris might have occurred in U.S. health care facilities and demonstrate the need for attention to infection control measures to control the spread of this pathogen.
Immunotherapy Immediately Following Transplantation for Multiple Myeloma: Early Recovery of Aggressive Cytotoxic Cells and Improved Immune Recovery.
Authors: Elizabeth Bengtson, Jia-Yan Wu, Thomas Fitzmaurice, Cornelius J. Cornell, Pamela Ely, Marc Gautier, John Hill, Christopher H. Lowrey, Kenneth Meehan
Journal: Blood (2004)
Norman Keith Ian McIver
Authors: James Douglas
Journal: BMJ (2016)

Norman Keith Ian McIver (“Nick”) was the key UK diving physician during the early years of the North Sea oil industry. He pioneered clinical treatments, medical support for the offshore gas industry, and medical standards. He succeeded Robin Cox, who had set up the North Sea Medical Centre at the Gorleston Medical Practice in Great Yarmouth, and he further developed the general and diving medical support services. The rush to extract gas from the southern sector of the North Sea off East Anglia introduced a new offshore industry that constructed gas platforms and pipelines. The technology to boost the UK economy and switch from coal gas to natural gas in the 1970s came from the USA’s Gulf of Mexico, with an attendant pioneering, and sometimes cowboy, spirit. Divers were required to spend as long as physiologically possible at 50 metres, which is the limit for air diving, in order to do heavy manual engineering construction underwater. The US navy had a bomb planting technique called surface decompression, which was applied commercially in the southern gas fields but produced a high rate of spinal decompression sickness when the military …
ATNT-21PRECLINICAL AND INITIAL PHASE 1 EXPERIENCE FOR USE OF MEBENDAZOLE AS UP FRONT THERAPY FOR HIGH GRADE GLIOMA
Authors: Gregory Riggins, Renyaun Bai, Gary Gallia
Journal: Neuro-Oncology (2015)

INTRODUCTION: Identifying drugs that can reach brain cancers in effective concentrations has been a serious challenge. There has been a body of evidence implicating anti-cancer mechanisms and utility for antihelminthics benzimidazoles, and preclinical and clinical development of repurposed mebendazole is gaining momentum. Mebendazole has been used safely as an anti-parasitic drug, and in high doses, in humans starting in 1972. METHODS: Multiple intracranial models of glioblastoma and medulloblastoma have been used for efficacy studies on intracranial tumors. Studies with orally administered mebendazole demonstrate favorable pharmacokinetics with 70 to 80% of mebendazole serum levels measured in the in the mouse brain and brain tumors. RESULTS: Our laboratory serendipitously identified benzimidazole anti-cancer activity in brain cancers and found that of the approved benzimidazoles, mebendazole showed the best survival benefit. We observe in preclinical testing it reaches effective concentrations in intracranial tumors, acts to prevent tubulin polymerization, has an additional anti-VEGR2 and anti-angiogenesis mechanisms and significantly improves survival in a variety of intracranial malignancy models. We have translated our preclinical findings into a Phase I trial, using mebendazole for upfront therapy, concurrent with temozolomide therapy for newly diagnosed patients with a high grade glioma. We have further improved mebendazole with drug combinations. CONCLUSION: The preclinical and phase 1 clinical findings are consistent with safe and possibly effective use of an improved formulation of oral mebendazole. We provide evidence that continued optimization of mebendazole based oral therapy and planning of future clinical trials may yield an additional tool for therapy of GBM and other intracranial tumors.
Value-Based Health Care (VBHC) in Sickle Cell Disease: A Dutch Initiative
Authors: Fia ten Brink, Anita W. Rijneveld, Marie-José J.A.G. Claessen, Amando J. Heesterman, Thea J. van Zon, Sonja A.M.C. Teuben, Cora J.D. Onna Van - Walraven, Alice M.A. Goncalves Silva, Francis van Veelen, Renée du Mortier, Marieke A.M.S. Joosten, Fred Petrij, Jan A. Hazelzet, Marjon H. Cnossen
Journal: Blood (2015)
O075 : Assessment of the transjugular porto-systemic shunt (TIPSS) in the management of complications of noncirrhotic portal hypertension
Authors: J. Bissonnette, J.-C. Garcia-Pagán, A. Albillos, C. Ferreira, F. Turon, L. Téllez, J.-C. Nault, M. Abdel Rehim, A. Sibert, P. Perreault, L. Bouchard, N. Carbonell, F. Trottier-Tellier, P.-E. Rautou, D. Valla, A. Plessier
Journal: Journal of Hepatology (2015)
Interleukin-7 Over-Expression Regulates T Cell Versus B Cell Lineage Development in the Thymus.
Authors: Nahed El Kassar, Philip J. Lucas, Frank Flomerfelt, Melinda Merchant, Catherine V. Bare, Semhar Mahmud, Crystal L. Mackall, Avinash Bhandoola, Ronald E. Gress
Journal: Blood (2004)
HOXB4 Enforces Equivalent Fates of ES-Cell-Derived and Adult Hematopoietic Cells.
Authors: Sandra Pilat, Carotta Sebastian, Schiedlmeier Bernhard, Modlich Ute, Kamino Kenji, Will Elke, Mairhofer Andreas, Steinlein Peter, Ostertag Wolfram, Beug Hartmut, Baum Christopher, Klump Hannes
Journal: Blood (2004)
Rehabilitation of the Physically Handicapped
Authors: H DIJON
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Prospective Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft Vs. Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)
Authors: Zaid Al-Kadhimi, Zartash Gul, Roberto Rodriguez, Wei Chen, Alice Mitchell, Muneer H. Abidi, Lois Ayash, Abhinav Deol, Lawrence G Lum, Voravit Ratanatharathorn, Joseph P. Uberti
Journal: Blood (2011)
Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: A multicentre study
Authors: Sing-Chien Yap, Jolien W. Roos-Hesselink, Elke Hoendermis, Werner Budts, Hubert W. Vliegen, Barbara J. Mulder, Arie P. Van Dijk, Martin J. Schalij, Willem Drenthen
Journal: Circulation (2006)
Progress Report of Combined Chemoradiotherapy Versus Radiotherapy Alone in Patients With Esophageal Cancer
Authors: M. Al-Sarraf, K. Martz, A. Herskovic, L. Leichman, J.S. Brindle, V.K. Vaitkevicius, J. Cooper, R. Byhardt, L. Davis, B. Emami
Journal: Journal of Clinical Oncology (1997)

The abstract of the report by Al-Sarraf, et al, entitled, "Progress Report of Combined Chemoradiotherapy Versus Radiotherapy Alone in Patients With Esophageal Cancer: An Intergroup Study" published in the January 1997 issue (J Clin Oncol 15:277–284, 1997) requires a clarification. As was correctly stated on p. 278, the second sentence of the abstract under Materials and Methods should have read: "CT consisted of cisplatin 75 mg/m 2 on day 1 and fluorouracil (5FU) 1,000 mg/m 2 /d on days 1 to 4 every 4 weeks with RT and every 3 weeks post-RT."
Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.
Authors: Eirini Katodritou, Evgenia Verrou, Anastasia Banti, Dimitra Mihou, Vassiliki Gastari, Christina Hadjiaggelidou, Dimitra Markala, Anna Lazaridou, Evangelos Terpos, Konstantinos Zervas
Journal: Blood (2007)
Sequencing the Multiple Myeloma Kinome: Absence of Mutation in Known Malignancy-Associated Kinases.
Authors: Jaime O. Claudio, Razi Khaja, Lihua Zhuang, Meenakshi Bali, Kamalanayani Sivananthan, Constantine C. Christopoulos, Rafael Fonseca, P. Leif Bergsagel, Stephen W. Scherer, A. Keith Stewart
Journal: Blood (2004)
CD34+CXCR4(CD184)+ Cells Differentiate Into Myeloid Dendritic Cell Progenitors
Authors: Robert E. Donahue, Ping Jin, Naoya Uchida, Aylin C. Bonifacino, Yu Tian, Johanna I. Klinman, Joseph J Mattapallil, Mark E. Metzger, Ann Williams, Daniela Malide, John F. Tisdale, David Stroncek
Journal: Blood (2013)
Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Authors: Sung-Nam Lim, Kyoo-Hyung Lee, Dae-Young Kim, Je-Hwan Lee, Jung-Hee Lee, Hyun-Sook Chi, Young-Don Joo, Won Sik Lee, Sang Min Lee, Seonyang Park, Inho Kim, Sang Kyun Sohn, Joon Ho Moon, Hun-Mo Ryoo, Sung Hwa Bae, Min Kyoung Kim, Deok-Hwan Yang, Hyeon-Seok Eom, Gyeong-Won Lee, Chul Won Jung, Jong-Ho Won, Hawk Kim, Jae-Hoon Lee, Ho-Jin Shin, Ho Young Kim, Myung Soo Hyun, Hyeoung Joon Kim
Journal: Blood (2014)
SCIO-469, a Potent and Selective Inhibitor of the p38a MAPK, Inhibits TNFa-Induced Adhesion of Multiple Myeloma Cells to Bone Marrow Stromal Cells Via Downregulation of Chemokines CXCL10/IP-10 and CCL8.
Authors: Aaron N. Nguyen, Gilbert O’ Young, Diana Quon, Debby Damm, Ann M. Kapoun, Linda S. Higgins, Tony A. Navas
Journal: Blood (2005)
Are Organic Foods Safer or Healthier Than Conventional Alternatives
Authors: Crystal Smith-Spangler, Margaret L. Brandeau, Grace E. Hunter, J. Clay Bavinger, Maren Pearson, Paul J. Eschbach, Vandana Sundaram, Hau Liu, Patricia Schirmer, Christopher Stave, Ingram Olkin, Dena M. Bravata
Journal: Annals of Internal Medicine (2012)

This systematic review compared the evidence from 237 studies on the health, nutritional, and safety characteristics of organic and conventional foods. It found that the published literature lacks ...
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada
Authors: Naveed Z. Janjua, Mei Chong, Margot Kuo, Ryan Woods, Jason Wong, Eric M. Yoshida, Morris Sherman, Zahid A. Butt, Hasina Samji, Darrel Cook, Amanda Yu, Maria Alvarez, Mark Tyndall, Mel Krajden
Journal: Journal of Hepatology (2016)
Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles
Authors: Prachi B. Shekhawat, Varsha B. Pokharkar
Journal: Acta Pharmaceutica Sinica B (2016)

Oral drug absorption is a process influenced by the physicochemical and biopharmaceutical properties of the drug and its inter-relationship with the gastrointestinal tract. Drug solubility, dissolution and permeability across intestinal barrier are the key parameters controlling absorption. This review provides an overview of the factors that affect drug absorption and the classification of a drug on the basis of solubility and permeability. The biopharmaceutical classification system (BCS) was introduced in early 90׳s and is a regulatory tool used to predict bioavailability problems associated with a new entity, thereby helping in the development of a drug product. Strategies to combat solubility and permeability issues are also discussed.
Inhibition of STAT5 by IL-1β or the Inhibitor of Janus Kinases Stimulates Dormant Human Leukemia Stem Cells and Sensitizes Them to Anti-Leukemia Agents.
Authors: Takayuki Ikezoe, Yang Jing, Chie Nishioka, Shinsuke Kojima, Asako Takeuchi, Akihito Yokoyama
Journal: Blood (2009)
Deletion of Any of BCR or ABL Gene on Derivative Chromosome 9 Is a Poor Prognostic Marker That Indicates Rapid Disease Progression in Chronic Myelogenous Leukemia.
Authors: Young Kyung Lee, Young Ree Kim, Cha Ja She, Sung-Soo Yoon, Young Soo Kim, Han Ik Cho, Hee Chan Kim, Yun Song Lee, Dong Soon Lee
Journal: Blood (2005)
ADAMTS13 Activity in Sickle Cell Disease: A Role in the Development of Clinical Vaso-Occlusion?.
Authors: John-John B. Schnog, Johanna Kremer-Hovinga, Sakir Akin, Ernan Ozveren, Soraya Krieg, Bernhard Lammle, Dees Brandjes, Melvin R. Mac Gillavry, Fred D. Muskiet, Ashley J. Duits
Journal: Blood (2004)
Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries
Authors: Lynette Denny, Silvia de Sanjose, Miriam Mutebi, Benjamin O Anderson, Jane Kim, Jose Jeronimo, Rolando Herrero, Karen Yeates, Ophira Ginsburg, Rengaswamy Sankaranarayanan
Journal: The Lancet (2016)
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Authors: Rodica Pop-Busui, Barbara H. Braffett, Bernie Zinman, Catherine Martin, Neil H. White, William H. Herman, Saul Genuth, Rose Gubitosi-Klug
Journal: Diabetes Care (2016)

To examine whether cardiovascular autonomic neuropathy (CAN) is an independent risk factor of cardiovascular disease (CVD) events during DCCT/EDIC.
<i>BRAF</i> and <i>NRAS</i> Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer
Authors: Matthew G. Summers, Christopher G. Smith, Timothy S. Maughan, Richard Kaplan, Valentina Escott-Price, Jeremy P. Cheadle
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Somatic mutation status at KRAS, BRAF, and NRAS is associated with prognosis in patients with advanced colorectal cancer (aCRC); however, it remains unclear whether there are intralocus, variant-specific differences in survival and other clinicopathologic parameters. Experimental Design: We profiled 2,157 aCRCs for somatic mutations in KRAS, BRAF, and NRAS and determined microsatellite instability status. We sought inter- and intralocus correlations between mutations and variant-specific associations with survival and clinicopathology. Results: KRAS mutations were rarely found together and those in codons 12 and 13 conferred poor prognosis [hazard ratio (HR), 1.44; 95% confidence interval (CI), 1.28–1.61; P = 6.4 × 10−10 and HR, 1.53; 95% CI, 1.26–1.86; P = 1.5 × 10−05, respectively]. For BRAF, more c.1781A&amp;gt;G (p.D594G) CRCs carried RAS mutations [14% (3/21)] compared with c.1799T&amp;gt;A (p.V600E) CRCs [1% (2/178), P = 9.0 × 10−03]. c.1799T&amp;gt;A (p.V600E) was associated with poor prognosis (HR, 2.60; 95% CI, 2.06–3.28; P = 1.0 × 10−15), whereas c.1781A&amp;gt;G (p.D594G) was not (HR, 1.30; 95% CI, 0.73–2.31; P = 0.37); this intralocus difference was significant (P = 0.04). More c.1799T&amp;gt;A (p.V600E) colorectal cancers were found in the right colon [47% (47/100)], compared with c.1781A&amp;gt;G (p.D594G) colorectal cancers [7% (1/15), P = 3.7 × 10−03]. For NRAS, 5% (3/60) of codon 61 mutant colorectal cancers had KRAS mutations compared with 44% (10/23) of codons 12 and 13 mutant colorectal cancers (P = 7.9 × 10−05). Codon 61 mutations conferred poor prognosis (HR, 1.47; 95% CI, 1.09–1.99; P = 0.01), whereas codons 12 and 13 mutations did not (HR, 1.29; 95% CI, 0.64–2.58; P = 0.48). Conclusions: Our data show considerable intralocus variation in the outcomes of mutations in BRAF and NRAS. These data need to be considered in patient management and personalized cancer therapy. Clin Cancer Res; 23(11); 2742–9. ©2016 AACR.
Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID
Authors: Andreas Hochhaus, Gert Ossenkoppele, Josy Reiffers, Ming Yao, Hirohiko Shibayama, Norbert Gattermann, Timothy P. Hughes, Giuseppe Saglio, Richard A. Larson, Albert Hoenekopp, Neil J. Gallagher, Richard Yu, Rick E. Blakesley, Clarisse Lobo, Hagop M. Kantarjian
Journal: Blood (2011)
Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy
Authors: Rochelle Payne Ondracek, Michael W Kattan, Christine Murekeyisoni, Changhong Yu, Eric C Kauffman, James R Marshall, James L Mohler
Journal: Journal of the National Comprehensive Cancer Network (2016)

Background: The Kattan postoperative radical prostatectomy (RP) nomogram is used to predict biochemical recurrence-free progression (BCRFP) after RP. However, external validation among contemporary patients using modern outcome definitions is limited. Methods: A total of 1,931 patients who underwent RP at Roswell Park Cancer Institute (RPCI) between 1993 and 2014 (median follow-up, 47 months; range, 0–244 months) were assessed for NCCN-defined biochemical failure (BF) and RPCI-defined treatment failure (TF). Actual rates of biochemical failure-free survival (BFS; defined as 1 – BF) and treatment failure-free survival (TFS; defined as 1 – TF) were compared with Kattan BCRFP nomogram predictions. Results: The Kattan BCRFP nomogram predictions at 5 and 10 years were predictive of BFS (area under the receiver operating characteristic curve [AUC], 0.772) and TFS (AUC, 0.774). The Kattan BCRFP nomogram tended to underestimate BFS and TFS compared with actual outcomes. The Kattan 5-year BCRFP predictions consistently overestimated actual 5-year BFS outcomes among subgroups of high- and intermediate-risk patients with at least 5-year outcomes. Conclusions: The Kattan BCRFP nomogram is a robust predictor of NCCN-defined BF in a large sample of patients with RP with substantial follow-up and modern, standardized failure definitions
Impact of Treatment on Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (MDS): A Report from the Erasme Study
Authors: Montserrat Arnan, Rosa Coll, Mar Tormo, José María Bastida, María Calbacho, Teresa Bernal, Fernando Ramos, Nieves Somolinos, Carmen Pedro, Manuel Albors, Inmaculada Marchante, Salut Brunet, Montse Rafel, David Valcárcel
Journal: Blood (2015)
PCM1-JAK2 Fusion Product Selectively Activates MAP-Kinase Pathway and Fails to Phosphorylate JAK2 and STAT5: Implications for Therapeutic Strategies.
Authors: Elena Masselli, Cristina Mecucci, Giuliana Gobbi, Cecilia Carubbi, Sabrina Bonomini, Lucia Prezioso, Elena Rossetti, Cecilia Caramatti, Marco Vitale, Franco Aversa
Journal: Blood (2012)
Comparison of Oxidant Stress and Damage-Related Responses after Total Body Irradiation Versus Total Marrow Irradiation in Rodents
Authors: Susanta Hui, Yutaka Takahashi, Shernan G. Holtan, Rezvan Azimi, Masashi Yagi, Jessie Ingvalson, Davis Seelig, Parham Alaei, Luke Arentsen, Lindsey Godin, Alex Domek, Michael Ehrhardt, Angela Panoskaltsis-Mortari
Journal: Blood (2014)
RNAi-Mediated Inhibition of Activated Protein C- A New Approach for Hemophilia Treatment
Authors: Ivanka Toudjarska, Zuhua Cai, Tim Racie, Julia Hettinger, Stuart Milstein, Brian R Bettencourt, Dinah WY Sah, David Bumcrot, John Maraganore, Akshay Vaishnaw
Journal: Blood (2011)
Shoulder pain: can one label satisfy everyone and everything?
Authors: Ann M Cools, Lori A Michener
Journal: British Journal of Sports Medicine (2016)

The labelling of non-traumatic shoulder pain related to the structures of the subacromial space has been debated for many years. Historically, labelling of shoulder diagnoses and exploring theories about the underlying causes of shoulder pain are interrelated. Many authors use the phrase ‘syndrome’ describing a combination of findings, often occurring together, with an unknown or heterogeneous underlying pathogenesis. As such, Dr Charles Neer introduced the diagnostic label of ‘subacromial impingement syndrome’ (SIS) of the shoulder in 1972. This label was based on the mechanism of structural impingement of the structures of the subacromial space. This concept has been the dominant theory of injury to the rotator cuff tendons and other structures in the subacromial space, and has served as the rationale for clinical tests, surgical procedures and rehabilitation protocols.

However, the label of SIS is now controversial, as recent evidence suggests that this concept does not fully explain the mechanism.1–3 Until a few years ago, SIS was a widely accepted ‘umbrella’ term for a number of possible underlying structural or biomechanical causes. Throughout the years, the description progressed from SIS to ‘impingement related shoulder pain’, with the growing opinion that ‘impingement’ represents a cluster of symptoms and a possible mechanism for the pain, rather than a pathoanatomic diagnose itself. The …